CSS
IMDX

Cubist Systematic Strategies’s Insight Molecular Diagnostics IMDX Stock Holding History

Cubist Systematic Strategies’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,036
Closed -$30K – 4499
2022
Q3 		$30K Buy
2,036
+674
+49% +$11.7K ﹤0.01% 4195
2022
Q2 		$25K Buy
+1,362
New +$31K ﹤0.01% 4187
2021
Q3 		– Sell
-670
Closed -$77K – 3122
2021
Q2 		$77K Sell
670
-722
-52% -$70.5K ﹤0.01% 2746
2021
Q1 		$144K Buy
+1,392
New +$132K ﹤0.01% 2572

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Cubist Systematic Strategies's IMDX Position: Q4 2022 in Review

Cubist Systematic Strategies sold out of Insight Molecular Diagnostics (IMDX) in Q4 2022, closing a stake of 2,036 shares — an estimated $30K sold.

Cubist Systematic Strategies first reported a position in IMDX in Q1 2021 and held it in 4 quarters. The position peaked at $144K in Q1 2021. 58 funds tracked by Wall St. Rank hold IMDX as of Q4 2022.

  • Cubist Systematic Strategies reported no remaining Insight Molecular Diagnostics position as of Q4 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 2,036 Insight Molecular Diagnostics shares in Q4 2022, an estimated $30K.
  • Cubist Systematic Strategies first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 4 quarters.
  • Cubist Systematic Strategies's Insight Molecular Diagnostics position peaked at $144K in Q1 2021.
  • 58 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2022.

Based on Cubist Systematic Strategies's 13F filing for Q4 2022, filed 14 Feb 2023.